Publications



Results 1-59 of 59 (Search time: 0.027 seconds).

Issue DateTitleAuthor(s)SourcescopusWOSFulltext/Archive link
12022Heat shock protein 90 inhibitor 17-AAG down-regulates thymidine phosphorylase expression and potentiates the cytotoxic effect of tamoxifen and erlotinib in human lung squamous carcinoma cellsJEN-CHUNG KO ; Chen, Jyh-Cheng; Hsieh, Jou-Min; Tseng, Pei-Yu; Chiang, Chen-Shan; Liu, Li-Ling; Chien, Chin-Cheng; Huang, I-Hsiang; Chang, Qiao-Zhen; Mu, Bo-Cheng; Lin, Yun-WeiBiochemical pharmacology01
22022Capsaicin Acts Through Reducing P38 MAPK-Dependent Thymidylate Synthase Expression to Enhance 5-Fluorouracil-Induced Cytotoxicity in Human Lung Cancer CellsTung C.-L.; Chen J.-C.; JEN-CHANG KO ; Liu L.-L.; Chien C.-C.; Huang I.-H.; Tsao Y.-C.; Cheng H.-H.; Chen T.-Y.; Yen T.-C.; Lin Y.-W.Natural Product Communications11
32022Nitroglycerin-induced downregulation of AKT- and ERK1/2-mediated radiation-sensitive 52 expression to enhance pemetrexed-induced cytotoxicity in human lung cancer cellsJEN-CHUNG KO Nitroglycerin-induced downregulation of AKT- and ERK1/2-mediated radiation-sensitive 52 expression to enhance pemetrexed-induced cytotoxicity in human lung cancer cells00
42021Functional Status After Pulmonary Rehabilitation as a Predictor of Weaning Success and Survival in Patients Requiring Prolonged Mechanical VentilationKeng L.-T.; Liang S.-K.; Tseng C.-P.; Wen Y.-F.; Tsou P.-H.; Chang C.-H.; Chang L.-Y.; Yu K.-L.; Lee M.-R.; JEN-CHANG KO Frontiers in Medicine11
52021Cross-talk between SOX2 and TGFb signaling regulates EGFR-TKI tolerance and lung cancer disseminationKuo M.-H.; Lee A.-C.; Hsiao S.-H.; Lin S.-E.; Chiu Y.-F.; Yang L.-H.; Yu C.-C.; Chiou S.-H.; Huang H.-N.; JEN-CHANG KO ; Chou Y.-T.Cancer Research1213
62021Treatment Options of First-Line Tyrosine Kinase Inhibitors and Subsequent Systemic Chemotherapy Agents for Advanced EGFR Mutant Lung Adenocarcinoma Patients: Implications From Taiwan Cancer Registry CohortLiang S.-K.; Keng L.-T.; Chang C.-H.; Wen Y.-F.; Lee M.-R.; Yang C.-Y.; Wang J.-Y.; JEN-CHANG KO ; Shih J.-Y.; Yu C.-J.Frontiers in Oncology11
72021Exploring volatile organic compounds in breath for high-accuracy prediction of lung cancerTsou P.-H.; Lin Z.-L.; Pan Y.-C.; Yang H.-C.; Chang C.-J.; Liang S.-K.; Wen Y.-F.; Chang C.-H.; Chang L.-Y.; Yu K.-L.; Liu C.-J.; Keng L.-T.; Lee M.-R.; JEN-CHANG KO ; Huang G.-H.; Li Y.-K.Cancers85
82021Downregulation of Xeroderma Pigmentosum Complementation Group C Expression by 17-Allylamino-17-Demethoxygeldanamycin Enhances Bevacizumab-Induced Cytotoxicity in Human Lung Cancer CellsChen J.-C.; JEN-CHANG KO ; Taso Y.-C.; Cheng H.-H.; Chen T.-Y.; Yen T.-C.; Lin Y.-W.Pharmacology23
92021Efficacy and safety of cone-beam computed tomography-derived augmented fluoroscopy combined with endobronchial ultrasound in peripheral pulmonary lesionsYu K.-L.; Yang S.-M.; Ko H.-J.; Tsai H.-Y.; JEN-CHANG KO ; Lin C.-K.; Ho C.-C.; Shih J.-Y.Respiration32
102021Downregulation of p38 MAPK Activation and Radiation-Sensitive 52 Expression Enhances 5-Fluorouracil and Erlotinib-Induced Cytotoxicity in Human Lung Squamous CellsJEN-CHUNG KO Pharmacology00
112020Effect of β-Blocker in Treatment-Na?ve Patients With Advanced Lung Adenocarcinoma Receiving First-Generation EGFR-TKIsChang C.-H.; Lee C.-H.; JEN-CHANG KO ; Chang L.-Y.; Lee M.-C.; Zhang J.-F.; Wang J.-Y.; Shih J.-Y.; Yu C.-J.Frontiers in Oncology45
122020Seroprevalence of Aspergillus IgG and disease prevalence of chronic pulmonary aspergillosis in a country with intermediate burden of tuberculosis: a prospective observational studyLee M.-R.; Huang H.-L.; Chen L.-C.; Yang H.-C.; JEN-CHANG KO ; Cheng M.-H.; Chong I.-W.; Lee L.-N.; Wang J.-Y.; Dimopoulos G.Clinical Microbiology and Infection1513
132020Nitroglycerin Enhances Cisplatin-Induced Cytotoxicity via AKT Inactivation and Thymidylate Synthase Downregulation in Human Lung Cancer CellsJEN-CHANG KO ; Chen J.-C.; Yen T.-C.; Chen T.-Y.; Ma P.-F.; Lin Y.-C.; Cheng H.-H.; Taso Y.-C.; Lin Y.-W.Pharmacology14
142020Clinical impact of using fluoroquinolone with low antimycobacterial activity on treatment delay in tuberculosis: Hospital-based and population-based cohort studyLee M.-R.; Lee C.-H.; Wang J.-Y.; Lee S.-W.; JEN-CHANG KO ; Lee L.-N.Journal of the Formosan Medical Association34
152020Nontuberculous mycobacterial lung disease epidemiology in Taiwan: A systematic reviewLee M.-R.; Chang L.-Y.; JEN-CHANG KO ; Wang H.-C.; Huang Y.-W.Journal of the Formosan Medical Association65
162019Outcome of stage IV cancer patients receiving in-hospital cardiopulmonary resuscitation: a population-based cohort studyLee M.-R.; Yu K.-L.; Kuo H.-Y.; Liu T.-H.; JEN-CHANG KO ; Tsai J.-S.; Wang J.-Y.Scientific Reports99
172019Factors associated with improvement in symptoms and quality of life for first-line EGFR-tyrosine kinase inhibitor treatment in patients with EGFR-mutated non-small-cell lung cancer - A multicenter prospective SMILE studyWei Y.-F.; Huang W.-T.; Liu T.-C.; Shieh J.-M.; Chian C.-F.; Wu M.-F.; Chang C.-C.; Lin C.-H.; JEN-CHANG KO ; Lin C.-M.; Hsia T.-C.Journal of Cancer55
182019Inhibition of thymidine phosphorylase expression by Hsp90 inhibitor potentiates the cytotoxic effect of salinomycin in human non-small-cell lung cancer cellsJEN-CHANG KO ; Chen J.-C.; Chen T.-Y.; Yen T.-C.; Ma P.-F.; Lin Y.-C.; Wu C.-H.; Peng Y.-S.; Zheng H.-Y.; Lin Y.-W.Toxicology33
192019Afatinib is effective in the treatment of lung adenocarcinoma with uncommon EGFR p.L747P and p.L747S mutationsLiang S.-K.; JEN-CHANG KO ; Yang J.C.-H.; Shih J.-Y.Lung Cancer2217
202019Capsaicin enhances erlotinib-induced cytotoxicity: Via AKT inactivation and excision repair cross-complementary 1 (ERCC1) down-regulation in human lung cancer cellsChen J.-C.; JEN-CHANG KO ; Yen T.-C.; Chen T.-Y.; Lin Y.-C.; Ma P.-F.; Lin Y.-W.Toxicology Research118
212018Prognostic factors of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma: A real-world, large cohort studyLiang S.-K.; Lee M.-R.; Liao W.-Y.; Ho C.-C.; JEN-CHANG KO ; Shih J.-Y.Oncotarget130
222018Psychological distress and coping strategies among women with incurable lung cancer: a qualitative studyLiao Y.-C.; Liao W.-Y.; Sun J.-L.; JEN-CHANG KO ; Yu C.-J.Supportive Care in Cancer1415
232017Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinomaLiang S.-K.; Hsieh M.-S.; Lee M.-R.; Keng L.-T.; JEN-CHANG KO ; Shih J.-Y.Oncotarget5146
242017Cementing an unwanted relationshipChang C.-H.; Keng L.-T.; JEN-CHANG KO Thorax00
252017Diabetes Mellitus and Latent Tuberculosis Infection: A Systemic Review and MetaanalysisLee M.-R.; Huang Y.-P.; Kuo Y.-T.; Luo C.-H.; Shih Y.-J.; Shu C.-C.; Wang J.-Y.; JEN-CHANG KO ; Yu C.-J.; Lin H.-H.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America6972
262017Gefitinib or erlotinib in previously treated non–small-cell lung cancer patients: a cohort study in TaiwanChang C.-H.; Lee C.-H.; JEN-CHANG KO ; Chang L.-Y.; Lee M.-C.; Wang J.-Y.; Yu C.-J.Cancer Medicine76
272017Tuberculosis contact investigation in an intermediate burden setting: implications from a large tuberculosis contact cohort in TaiwanLee M.-R.; Ho C.-M.; Lee C.-H.; Lee M.-C.; Chang L.-Y.; Yu K.-L.; JEN-CHANG KO ; Wang J.-Y.; Wang J.-T.; Lee L.-N.The European respiratory journal1313
282016Acquisition of Mycobacterium abscessus among ventilator-dependent patients in Taiwan chronic respiratory care facilitiesLee M.-R.; Tsai C.-J.; Hu J.-Y.; Lee S.-W.; JEN-CHANG KO ; Wang H.-C.; Yu C.-J.; Lee L.-N.; Hsueh P.-R.Future Microbiology55
292016Salinomycin enhances cisplatin-induced cytotoxicity in human lung cancer cells via down-regulation of AKT-dependent thymidylate synthase expressionJEN-CHANG KO ; Zheng H.-Y.; Chen W.-C.; Peng Y.-S.; Wu C.-H.; Wei C.-L.; Chen J.-C.; Lin Y.-W.Biochemical Pharmacology88
302016Vorinostat enhances the cisplatin-mediated anticancer effects in small cell lung cancer cellsPan C.-H.; Chang Y.-F.; Lee M.-S.; Wen B.-C.; JEN-CHANG KO ; Liang S.-K.; Liang M.-C.BMC Cancer2721
312016Astaxanthin down-regulates Rad51 expression via inactivation of AKT kinase to enhance mitomycin C-induced cytotoxicity in human non-small cell lung cancer cellsJEN-CHANG KO ; Chen J.-C.; Wang T.-J.; Zheng H.-Y.; Chen W.-C.; Chang P.-Y.; Lin Y.-W.Biochemical Pharmacology4242
322015Factors associated with subsequent nontuberculous mycobacterial lung disease in patients with a single sputum isolate on initial examinationLee M.-R.; Yang C.-Y.; Shu C.-C.; Lin C.-K.; Wen Y.-F.; Lee S.-W.; JEN-CHANG KO ; Wang J.-Y.; Lee L.-N.; Yu C.-J.Clinical Microbiology and Infection1917
332015Resveratrol Enhances Etoposide-Induced Cytotoxicity through Down-Regulating ERK1/2 and AKT-Mediated X-ray Repair Cross-Complement Group 1 (XRCC1) Protein Expression in Human Non-Small-Cell Lung Cancer CellsJEN-CHANG KO ; Syu J.-J.; Chen J.-C.; Wang T.-J.; Chang P.-Y.; Chen C.-Y.; Jian Y.-T.; Jian Y.-J.; Lin Y.-W.Basic and Clinical Pharmacology and Toxicology1914
342015Down-regulation of MSH2 expression by Hsp90 inhibition enhances cytotoxicity affected by tamoxifen in human lung cancer cellsJEN-CHANG KO ; Chiu H.-C.; Syu J.-J.; Chen C.-Y.; Jian Y.-T.; Huang Y.-J.; Wo T.-Y.; Jian Y.-J.; Chang P.-Y.; Wang T.-J.; Lin Y.-W.Biochemical and Biophysical Research Communications88
352015Minocycline enhances mitomycin C-induced cytotoxicity through down-regulating ERK1/2-mediated Rad51 expression in human non-small cell lung cancer cellsJEN-CHANG KO ; Wang T.-J.; Chang P.-Y.; Syu J.-J.; Chen J.-C.; Chen C.-Y.; Jian Y.-T.; Jian Y.-J.; Zheng H.-Y.; Chen W.-C.; Lin Y.-W.Biochemical Pharmacology44
362014Tamoxifen enhances erlotinib-induced cytotoxicity through down-regulating AKT-mediated thymidine phosphorylase expression in human non-small-cell lung cancer cellsJEN-CHANG KO ; Chiu H.-C.; Syu J.-J.; Jian Y.-J.; Chen C.-Y.; Jian Y.-T.; Huang Y.-J.; Wo T.-Y.; Lin Y.-W.Biochemical Pharmacology2424
372014Clinical characteristics and outcomes of patients with pleural infections due to Stenotrophomonas maltophilia at a medical center in Taiwan, 2004-2012Lee M.-R.; Wang H.-C.; Yang C.-Y.; Lin C.-K.; Kuo H.-Y.; JEN-CHANG KO ; Sheng W.-H.; Lee L.-N.; Yu C.-J.; Hsueh P.-R.European Journal of Clinical Microbiology and Infectious Diseases87
382014Bacteraemia caused by Mycobacterium abscessus subsp. abscessus and M. abscessus subsp. bolletii: Clinical features and susceptibilities of the isolatesLee M.-R.; JEN-CHANG KO ; Liang S.-K.; Lee S.-W.; Yen D.H.-T.; Hsueh P.-R.International Journal of Antimicrobial Agents1313
392013Inhibition of p38 MAPK-dependent MutS homologue-2 (MSH2) expression by metformin enhances gefitinib-induced cytotoxicity in human squamous lung cancer cellsJEN-CHANG KO ; Chiu H.-C.; Wo T.-Y.; Huang Y.-J.; Tseng S.-C.; Huang Y.-C.; Chen H.-J.; Syu J.-J.; Chen C.-Y.; Jian Y.-T.; Jian Y.-J.; Lin Y.-W.Lung Cancer1918
402013Metformin induces cytotoxicity by down-regulating thymidine phosphorylase and excision repair cross-complementation 1 expression in non-small cell lung cancer cellsJEN-CHANG KO ; Huang Y.-C.; Chen H.-J.; Tseng S.-C.; Chiu H.-C.; Wo T.-Y.; Huang Y.-J.; Weng S.-H.; Chiou R.Y.Y.; Lin Y.-W.Basic and Clinical Pharmacology and Toxicology1514
412013Pemetrexed downregulates ERCC1 expression and enhances cytotoxicity effected by resveratrol in human nonsmall cell lung cancer cellsChen R.-S.; JEN-CHANG KO ; Chiu H.-C.; Wo T.-Y.; Huang Y.-J.; Tseng S.-C.; Chen H.-J.; Huang Y.-C.; Jian Y.-J.; Lee W.-T.; Lin Y.-W.Naunyn-Schmiedeberg's Archives of Pharmacology88
422012HSP90 inhibition induces cytotoxicity via down-regulation of Rad51 expression and DNA repair capacity in non-small cell lung cancer cellsJEN-CHANG KO ; Chen H.-J.; Huang Y.-C.; Tseng S.-C.; Weng S.-H.; Wo T.-Y.; Huang Y.-J.; Chiu H.-C.; Tsai M.-S.; Chiou R.Y.Y.; Lin Y.-W.Regulatory Toxicology and Pharmacology1616
432011Modulation of Rad51, ERCC1, and thymidine phosphorylase by emodin result in synergistic cytotoxic effect in combination with capecitabineJEN-CHANG KO ; Tsai M.-S.; Kuo Y.-H.; Chiu Y.-F.; Weng S.-H.; Su Y.-C.; Lin Y.-W.Biochemical Pharmacology2423
442011Up-regulation of extracellular signal-regulated kinase 1/2-dependent thymidylate synthase and thymidine phosphorylase contributes to cisplatin resistance in human non-small-cell lung cancer cellsJEN-CHANG KO ; Tsai M.-S.; Chiu Y.-F.; Weng S.-H.; Kuo Y.-H.; Lin Y.-W.Journal of Pharmacology and Experimental Therapeutics1819
452011Curcumin enhances the mitomycin C-induced cytotoxicity via downregulation of MKK1/2-ERK1/2-mediated Rad51 expression in non-small cell lung cancer cellsJEN-CHANG KO ; Tsai M.-S.; Weng S.-H.; Kuo Y.-H.; Chiu Y.-F.; Lin Y.-W.Toxicology and Applied Pharmacology3431
462010Suppression of ERCC1 and Rad51 expression through ERK1/2 inactivation is essential in emodin-mediated cytotoxicity in human non-small cell lung cancer cellsJEN-CHANG KO ; Su Y.-J.; Lin S.-T.; Jhan J.-Y.; Ciou S.-C.; Cheng C.-M.; Lin Y.-W.Biochemical Pharmacology6560
472010Emodin enhances cisplatin-induced cytotoxicity via down-regulation of ERCC1 and inactivation of ERK1/2JEN-CHANG KO ; Su Y.-J.; Lin S.-T.; Jhan J.-Y.; Ciou S.-C.; Cheng C.-M.; Chiu Y.-F.; Kuo Y.-H.; Tsai M.-S.; Lin Y.-W.Lung Cancer4541
482009Roles of MKK1/2-ERK1/2 and phosphoinositide 3-kinase-AKT signaling pathways in erlotinib-induced Rad51 suppression and cytotoxicity in human non-small cell lung cancer cellsJEN-CHANG KO ; Ciou S.-C.; Jhan J.-Y.; Cheng C.-M.; Su Y.-J.; Chuang S.-M.; Lin S.-T.; Chang C.-C.; Lin Y.-W.Molecular Cancer Research4340
492009Emodin enhances gefitinib-induced cytotoxicity via Rad51 downregulation and ERK1/2 inactivationChen R.-S.; Jhan J.-Y.; Su Y.-J.; Lee W.-T.; Cheng C.-M.; Ciou S.-C.; Lin S.-T.; Chuang S.-M.; JEN-CHANG KO ; Lin Y.-W.Experimental Cell Research2725
502009The role of celecoxib in Rad51 expression and cell survival affected by gefitinib in human non-small cell lung cancer cellsJEN-CHANG KO ; Wang L.-H.; Jhan J.-Y.; Ciou S.-C.; Hong J.-H.; Lin S.-T.; Lin Y.-W.Lung Cancer99
512008Involvement of Rad51 in cytotoxicity induced by epidermal growth factor receptor inhibitor (gefitinib, Iressa R) and chemotherapeutic agents in human lung cancer cellsJEN-CHANG KO ; Ciou S.-C.; Cheng C.-M.; Wang L.-H.; Hong J.-H.; Jheng M.-Y.; Ling S.-T.; Lin Y.-W.Carcinogenesis5554
522008The role of repair protein Rad51 in synergistic cytotoxicity and mutagenicity induced by epidermal growth factor receptor inhibitor (Gefitinib, IressaR) and benzo[a]pyrene in human lung cancerJEN-CHANG KO ; Hong J.-H.; Wang L.-H.; Lin Y.-W.Experimental Cell Research1414
532008Role of repair protein Rad51 in regulating the response to gefitinib in human non-small cell lung cancer cellsJEN-CHANG KO ; Hong J.-H.; Wang L.-H.; Cheng C.-M.; Ciou S.-C.; Lin S.-T.; Jheng M.-Y.; Lin Y.-W.Molecular Cancer Therapeutics3734
542005Disseminated coccidioidomycosis [8]Wang C.-Y.; Jerng J.-S.; JEN-CHANG KO ; Lin M.-F.; Hsiao C.-H.; Lee L.-N.; Hsueh P.-R.; Kuo S.-H.Emerging Infectious Diseases1411
552004Dual and opposing roles of ERK in regulating G1 and S-G 2/M delays in A549 cells caused by hyperoxiaJEN-CHANG KO ; Wang Y.-T.; Yang J.-L.Experimental Cell Research1714
561994Ultrasonographic evaluation of peridiaphragmatic lesions: A prospective studyJEN-CHANG KO ; Yang P.-C.; Chang D.-B.; Yu C.-J.; Lee L.-N.; Kuo S.-H.; Luh K.-T.Journal of Medical Ultrasound6
571994Superior vena cava syndrome: Rapid histologic diagnosis by ultrasound- guided transthoracic needle aspiration biopsyJEN-CHANG KO ; Yang P.-C.; Yuan A.; Chang D.-B.; Yu C.-J.; Wu H.-D.; Lee L.-N.; Kuo S.-H.; Luh K.-T.American Journal of Respiratory and Critical Care Medicine2011
581994Panhypopituitarism caused by solitary parasellar metastasis from lung cancerJEN-CHANG KO ; Yang P.-C.; Huang T.-S.; Yeh K.-H.; Kuo S.-H.; Luh K.T.Chest1917
591992Lobar bronchioloalveolar carcinoma: an ultrasound study.JEN-CHANG KO ; Yang P.C.; Luh K.T.; Kuo S.H.; Chang D.B.; Yu C.J.Journal of the Formosan Medical Association = Taiwan yi zhi30